EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing

Aleksandra Murzyn, Justyna Orzeł, Natalia Obajtek, Anna Mróz, Dominika Miodowska, Patrycja Bojdo, Bartosz Gąsiorkiewicz, Paulina Koczurkiewicz-Adamczyk, Kamil Piska iD, Elżbieta Pękala

Cancer Chemotherapy and Pharmacology · 2024-08 · 94 (2) · 123-139

DOI: 10.1007/s00280-024-04693-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 04.07.2024. Verfasst von Aleksandra Murzyn und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland. Hauptthemen laut MEDLINE: Aclarubicin, Antineoplastic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki, Uniwersytet Jagielloński Collegium Medicum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aclarubicin (aclacinomycin A) is one of the anthracycline antineoplastic antibiotics with a multifaceted mechanism of antitumor activity. As a second-generation drug, it offers several advantages compared to standard anthracycline drugs such as doxorubicin or daunorubicin, which could position it as a potential blockbuster drug in antitumor therapy. Key mechanisms of action for aclarubicin include the inhibition of both types of topoisomerases, suppression of tumor invasion processes, generation of reactive oxygen species, inhibition of chymotrypsin-like activity, influence on cisplatin degradation, and inhibition of angiogenesis. Therefore, aclarubicin appears to be an ideal candidate for antitumor therapy. However, despite initial interest in its clinical applications, only a limited number of high-quality trials have been conducted thus far. Aclarubicin has primarily been evaluated as an induction therapy in acute myeloid and lymphoblastic leukemia. Studies have indicated that aclarubicin may hold significant promise for combination therapies with other anticancer drugs, although further research is needed to confirm its potential. This paper provides an in-depth exploration of aclarubicin’s diverse mechanisms of action, its pharmacokinetics, potential toxicity, and the clinical trials in which it has been investigated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AclarubicinAntineoplastic AgentsHumansAnimalsNeoplasms

Stichwörter der Autor:innen

Aclacinomycin AAclarubicinAnthracyclineAntibioticAntineoplastic drugAntitumor therapy

Substanzen

AclarubicinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland.
  • Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland. kamil.piska@uj.edu.pl.

ORCID-Profile: Kamil Piska

Förderung

  • Narodowe Centrum Nauki
  • Uniwersytet Jagielloński Collegium Medicum

Zitieren

APA

Murzyn, A., Orzeł, J., Obajtek, N., Mróz, A., Miodowska, D., Bojdo, P., Gąsiorkiewicz, B., Koczurkiewicz-Adamczyk, P., Piska, K., & Pękala, E. (2024). Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing. Cancer Chemotherapy and Pharmacology, 94(2), 123-139. https://doi.org/10.1007/s00280-024-04693-1

Vancouver

Murzyn A, Orzeł J, Obajtek N, Mróz A, Miodowska D, Bojdo P, et al. Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing. Cancer Chemotherapy and Pharmacology. 2024;94(2):123-139. doi:10.1007/s00280-024-04693-1

BibTeX
@article{Murzyn2024,
  author = {Murzyn, Aleksandra and Orzeł, Justyna and Obajtek, Natalia and Mróz, Anna and Miodowska, Dominika and Bojdo, Patrycja and Gąsiorkiewicz, Bartosz and Koczurkiewicz-Adamczyk, Paulina and Piska, Kamil and Pękala, Elżbieta},
  title = {Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  volume = {94},
  number = {2},
  pages = {123--139},
  doi = {10.1007/s00280-024-04693-1}
}
Kostenlos starten →